{"id":"ilaprazole-enteric-coated-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL2106370","moleculeType":"Small molecule","molecularWeight":"366.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ilaprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This reduces intragastric acidity and allows healing of acid-related lesions. It is a benzimidazole-based PPI with a mechanism similar to omeprazole and lansoprazole.","oneSentence":"Ilaprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:05.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric ulcer"},{"name":"Duodenal ulcer"},{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Acid-related gastrointestinal disorders"}]},"trialDetails":[{"nctId":"NCT03342456","phase":"PHASE4","title":"The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2017-12-13","conditions":"Duodenal Ulcer Due to Helicobacter Pylori","enrollment":184},{"nctId":"NCT02401477","phase":"PHASE4","title":"Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2014-12","conditions":"Helicobacter Infections","enrollment":90},{"nctId":"NCT02352701","phase":"","title":"Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2012-12","conditions":"Helicobacter Infections","enrollment":320}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"THROMBOCYTOPENIA"},{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"DEATH"},{"count":1,"reaction":"GRANULOCYTOPENIA"},{"count":1,"reaction":"MYELOSUPPRESSION"},{"count":1,"reaction":"SUSPECTED DRUG-INDUCED LIVER INJURY"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ilaprazole Enteric-Coated Tablets","genericName":"Ilaprazole Enteric-Coated Tablets","companyName":"The Third Xiangya Hospital of Central South University","companyId":"the-third-xiangya-hospital-of-central-south-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ilaprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Gastric ulcer, Duodenal ulcer, Gastroesophageal reflux disease (GERD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}